Search
Semaglutide Treatment Options in Canada
A collection of 85 research studies where Semaglutide is the interventional treatment. These studies are located in the Canada . Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
37 - 48 of 85
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
Completed
The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must take one tablet with water every morning on an empty stomach and not eat or drink anything for at least 30 minutes. The study will last for about 3.5-5 years. Participants will have up to 25 clinic visits and 1 phone ca... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/27/2025
Locations: Healthscan Clinical Trials,LLC., Montgomery, Alabama +472 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Active Not Recruiting
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Aurora FDRC Inc., Costa Mesa, California +23 locations
Conditions: Obesity
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
Completed
This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in people taking semaglutide (a new medicine) to people taking "dummy" medicine.
Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama +92 locations
Conditions: Obesity
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
Recruiting
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Toronto General Hospital, Toronto, Ontario
Conditions: Kidney Transplant Recipients
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Completed
The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/07/2025
Locations: University of Alabama at Birmingham Hospital, Birmingham, Alabama +241 locations
Conditions: Nonalcoholic Steatohepatitis
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Not Yet Recruiting
The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is:
Does an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity?
Participants will either participate in one of three groups:
* Nutrition: Participant will only have a regular follow-u... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Quebec
Conditions: Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
Active Not Recruiting
The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease. Semaglutide is a medicine that doctors can prescribe in some countries for the treatment of type 2 diabetes and excess body weight. This study will help us understand whether semaglutide can also be used for the treatment of Alzheimer's disease. The study will last for about 77 weeks. In the first 12 weeks of treatment, participant... Read More
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
01/02/2025
Locations: Banner Sun Health Research Institute, Sun City, Arizona +9 locations
Conditions: Alzheimers Disease
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
Completed
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +66 locations
Conditions: Obesity, Diabetes Mellitus, Type 2
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
Recruiting
A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose levels. Primarily designed for managing type 1 diabetes, this system has demonstrated significant benefits in previous studies. Yet, despite these advantages, certain challenges persist.
Semaglutide, utilized in treating type 2 diabetes and obesity, is a once-weekly injectabl... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/13/2024
Locations: Research Institute of the McGill University Health Centre, Montreal, Quebec
Conditions: Type 1 Diabetes, Diabetes Mellitus
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
Completed
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
12/06/2024
Locations: Research Site, Box Hill, Not set +82 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Active Not Recruiting
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/28/2024
Locations: The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 3, Chandler, Arizona +174 locations
Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV
Recruiting
This study is conducted to compare four different tablets containing the investigational medicine semaglutide at the same dose. It is done to test how semaglutide in each of the tablet versions is taken up in the body. Which treatments participants will receive is decided by chance. The study will last for about 28 weeks. The study will enroll healthy male participants.
Gender:
MALE
Ages:
Between 18 years and 64 years
Trial Updated:
11/18/2024
Locations: Altasciences, Montreal, Quebec
Conditions: Healthy Volunteers Type 2 Diabetes
37 - 48 of 85